Roche announces next stage in breakthrough research trial
At the European Huntington’s Disease Network conference in Vienna, pharmaceutical company Roche gave an update on the RG6042 antisense/gene silencing drug trial (formerly IONIS HTTRx).
They have announced that the world’s first phase three study that will test a molecule designed to lower the huntingtin protein will take place. This will be a global study taking place over 80 – 90 sites across 15 countries. These sites (usually HD clinics in hospitals) are yet to be determined. It will recruit 660 people. Sites will be announced over the coming months and recruitment is expected to begin at the end of this year.
In addition, they are recruiting to a natural history study which is a 15 month observational trial where no drugs will be given. The goal is to try to understand the role of the mutant protein.
Cath Stanley, Chief Executive, said:
“Families affected by Huntington’s have been keen to hear the next steps in this breakthrough research and so this will come as welcome news.”
Information about the sites involved in the study will be shared on a progressive basis. Once a site is nearly ready to enrol patients, Roche will update the information online at clinicaltrials.gov
The Huntington's disease research news website HDBuzz has shared a useful overview of the research and the next steps for the investigations. Read the article here
To keep up to date with Huntington's disease research news sign up to email alerts at HDBuzz.net
At the European Huntington’s Disease Network conference in Vienna, pharmaceutical company Roche gave an update on the RG6042 antisense/gene silencing drug trial (formerly IONIS HTTRx).
They have announced that the world’s first phase three study that will test a molecule designed to lower the huntingtin protein will take place. This will be a global study taking place over 80 – 90 sites across 15 countries. These sites (usually HD clinics in hospitals) are yet to be determined. It will recruit 660 people. Sites will be announced over the coming months and recruitment is expected to begin at the end of this year.
In addition, they are recruiting to a natural history study which is a 15 month observational trial where no drugs will be given. The goal is to try to understand the role of the mutant protein.
Cath Stanley, Chief Executive, said:
“Families affected by Huntington’s have been keen to hear the next steps in this breakthrough research and so this will come as welcome news.”
Information about the sites involved in the study will be shared on a progressive basis. Once a site is nearly ready to enrol patients, Roche will update the information online at clinicaltrials.gov
The Huntington's disease research news website HDBuzz has shared a useful overview of the research and the next steps for the investigations. Read the article here
To keep up to date with Huntington's disease research news sign up to email alerts at HDBuzz.net